Artiva Total Stockholder Equity vs Total Current Liabilities Analysis
ARTV Stock | 10.48 0.63 5.67% |
Artiva Biotherapeutics, financial indicator trend analysis is way more than just evaluating Artiva Biotherapeutics, prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Artiva Biotherapeutics, is a good investment. Please check the relationship between Artiva Biotherapeutics, Total Stockholder Equity and its Total Current Liabilities accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Artiva Biotherapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Total Stockholder Equity vs Total Current Liabilities
Total Stockholder Equity vs Total Current Liabilities Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Artiva Biotherapeutics, Total Stockholder Equity account and Total Current Liabilities. At this time, the significance of the direction appears to have pay attention.
The correlation between Artiva Biotherapeutics,'s Total Stockholder Equity and Total Current Liabilities is -0.83. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Artiva Biotherapeutics, Common, assuming nothing else is changed. The correlation between historical values of Artiva Biotherapeutics,'s Total Stockholder Equity and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Artiva Biotherapeutics, Common are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Total Stockholder Equity i.e., Artiva Biotherapeutics,'s Total Stockholder Equity and Total Current Liabilities go up and down completely randomly.
Correlation Coefficient | -0.83 |
Relationship Direction | Negative |
Relationship Strength | Significant |
Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Total Current Liabilities
Total Current Liabilities is an item on Artiva Biotherapeutics, balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Artiva Biotherapeutics, Common are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most indicators from Artiva Biotherapeutics,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Artiva Biotherapeutics, current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Artiva Biotherapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. Selling General Administrative is likely to climb to about 14.3 M in 2024, whereas Tax Provision is likely to drop slightly above 68.8 K in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 248K | 1.2M | 2.3M | 2.4M | Total Operating Expenses | 55.3M | 64.8M | 64.2M | 55.7M |
Artiva Biotherapeutics, fundamental ratios Correlations
Click cells to compare fundamentals
Artiva Biotherapeutics, Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Artiva Stock Analysis
When running Artiva Biotherapeutics,'s price analysis, check to measure Artiva Biotherapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Artiva Biotherapeutics, is operating at the current time. Most of Artiva Biotherapeutics,'s value examination focuses on studying past and present price action to predict the probability of Artiva Biotherapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Artiva Biotherapeutics,'s price. Additionally, you may evaluate how the addition of Artiva Biotherapeutics, to your portfolios can decrease your overall portfolio volatility.